Literature DB >> 28293028

Hepatitis: MicroRNA antagonists: promising antiviral agents against HCV and other viruses?

Jean-Michel Pawlotsky1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28293028     DOI： 10.1038/nrgastro.2017.28

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


× No keyword cloud information.
  10 in total

Review 1.  MicroRNAs and their targets: recognition, regulation and an emerging reciprocal relationship.

Authors:  Amy E Pasquinelli
Journal:  Nat Rev Genet       Date:  2012-03-13       Impact factor: 53.242

2.  Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial.

Authors:  Meike H van der Ree; J Marleen de Vree; Femke Stelma; Sophie Willemse; Marc van der Valk; Svend Rietdijk; Richard Molenkamp; Janke Schinkel; Ad C van Nuenen; Ulrich Beuers; Salah Hadi; Marten Harbers; Eva van der Veer; Kai Liu; John Grundy; Amy K Patick; Adam Pavlicek; Jacqueline Blem; Michael Huang; Paul Grint; Steven Neben; Neil W Gibson; Neeltje A Kootstra; Hendrik W Reesink
Journal:  Lancet       Date:  2017-01-11       Impact factor: 79.321

3.  Hepatitis C Drugs: Is Next Generation the Last Generation?

Authors:  Jean-Michel Pawlotsky
Journal:  Gastroenterology       Date:  2016-08-30       Impact factor: 22.682

4.  MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis.

Authors:  Wei-Chih Tsai; Sheng-Da Hsu; Chu-Sui Hsu; Tsung-Ching Lai; Shu-Jen Chen; Roger Shen; Yi Huang; Hua-Chien Chen; Chien-Hsin Lee; Ting-Fen Tsai; Ming-Ta Hsu; Jaw-Ching Wu; Hsien-Da Huang; Ming-Shi Shiao; Michael Hsiao; Ann-Ping Tsou
Journal:  J Clin Invest       Date:  2012-07-23       Impact factor: 14.808

Review 5.  Unraveling the Mysterious Interactions Between Hepatitis C Virus RNA and Liver-Specific MicroRNA-122.

Authors:  Peter Sarnow; Selena M Sagan
Journal:  Annu Rev Virol       Date:  2016-08-17       Impact factor: 10.431

6.  Treatment of HCV infection by targeting microRNA.

Authors:  Harry L A Janssen; Hendrik W Reesink; Eric J Lawitz; Stefan Zeuzem; Maribel Rodriguez-Torres; Keyur Patel; Adriaan J van der Meer; Amy K Patick; Alice Chen; Yi Zhou; Robert Persson; Barney D King; Sakari Kauppinen; Arthur A Levin; Michael R Hodges
Journal:  N Engl J Med       Date:  2013-03-27       Impact factor: 91.245

7.  MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib.

Authors:  Shoumei Bai; Mohd W Nasser; Bo Wang; Shu-Hao Hsu; Jharna Datta; Huban Kutay; Arti Yadav; Gerard Nuovo; Pawan Kumar; Kalpana Ghoshal
Journal:  J Biol Chem       Date:  2009-09-02       Impact factor: 5.157

8.  Cellular cofactors affecting hepatitis C virus infection and replication.

Authors:  Glenn Randall; Maryline Panis; Jacob D Cooper; Timothy L Tellinghuisen; Karen E Sukhodolets; Sebastien Pfeffer; Markus Landthaler; Pablo Landgraf; Sherry Kan; Brett D Lindenbach; Minchen Chien; David B Weir; James J Russo; Jingyue Ju; Michael J Brownstein; Robert Sheridan; Chris Sander; Mihaela Zavolan; Thomas Tuschl; Charles M Rice
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-06       Impact factor: 11.205

9.  Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice.

Authors:  Thazha P Prakash; Mark J Graham; Jinghua Yu; Rick Carty; Audrey Low; Alfred Chappell; Karsten Schmidt; Chenguang Zhao; Mariam Aghajan; Heather F Murray; Stan Riney; Sheri L Booten; Susan F Murray; Hans Gaus; Jeff Crosby; Walt F Lima; Shuling Guo; Brett P Monia; Eric E Swayze; Punit P Seth
Journal:  Nucleic Acids Res       Date:  2014-07-03       Impact factor: 16.971

10.  What are the pros and cons of the use of host-targeted agents against hepatitis C?

Authors:  Jean-Michel Pawlotsky
Journal:  Antiviral Res       Date:  2014-02-26       Impact factor: 5.970
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.